# US 2026/0091006 A1 · Dosage forms of mirdametinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091006 A1
- Document ID: US20260091006A1
- Status: Published application
- Kind: A1
- Application number: 19/267,096
- Filed: 2025-07-11
- Published: 2026-04-02
- Earliest claimed: 2023-03-16
- Assignees: Springworks Therapeutics, Inc.
- Applicants: SpringWorks Therapeutics, Inc.
- Inventors: Piero L. RUGGIERO; Kristin PATTERSON; Mark HATCHER; Jiping LIU; Uchenna H. ILOEJE; Abraham J. LANGSETH
- Web page: https://patentgrep.com/patent/US20260091006A1

## CPC

- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61J 3/07: into the form of capsules or similar small containers for oral use
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C07C 259/10: having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametinib having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametinib treatments.

## Claims

### Claim 1

An oral dosage form comprising (a) 0.5, 1, or 2 mg mirdametinib having a d50 of 1 to 30 microns and (b) one or more pharmaceutically acceptable excipients.

### Claim 2 (depends on 1)

The oral dosage form of claim 1, wherein the mirdametinib has a d50 of 1 to 25 microns.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The oral dosage form of claim 1, wherein the dosage form is a capsule prepared by (i) roller compaction of a blend of the mirdametinib and one or more pharmaceutically acceptable excipients and (ii) encapsulating the compacted blend into a capsule.

### Claim 5 (depends on 1)

The oral dosage form of claim 1, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, an AUC0-12h less than 400 ng·h/mL, a Cmax no more than 40 ng/ml, or both.

### Claim 6 (depends on 5)

The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, an AUC0-12h less than 200 ng·h/mL.

### Claim 7 (depends on 5)

The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, AUC0-12h less than 100 ng·h/mL.

### Claim 8 (depends on 5)

The oral dosage form claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, a Cmax no more than 32 ng/mL.

### Claim 9 (depends on 5)

The oral dosage form of claim 5, wherein the dosage form provides upon oral administration, on the first day of treatment with mirdametinib, a Cmax no more than 30 ng/mL.

### Claim 10 (depends on 1)

The oral dosage form of claim 1, wherein the dosage form is a capsule.

### Claim 11 (depends on 1)

The oral dosage form of claim 1, wherein the dosage form is a tablet.

### Claim 12 (depends on 1)

The oral dosage form of claim 1, wherein the dosage form is a dispersible tablet.

### Claim 13 (depends on 1)

A method of treating a human patient who has neurofibromatosis type 1 (NF1) comprising orally administering an effective amount of one or more oral dosage forms of claim 1 to the patient.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The method of claim 13, wherein
(a) for a patient having a body surface area of 0.4 to 0.69 m2, the patient is initially administered 1 mg mirdametinib twice daily,
(b) for a patient having a body surface area of 0.7 to 1.04 m2, the patient is initially administered 2 mg mirdametinib twice daily,
(c) for a patient having a body surface area of 1.05 to 1.49 m2, the patient is initially administered 3 mg mirdametinib twice daily, and
(d) for a patient having a body surface area of at least 1.5 m2, the patient is initially administered 4 mg mirdametinib twice daily.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The method of claim 15, wherein the patient is less than 12 years of age.

### Claim 18 (depends on 15)

The method of claim 15, wherein the mirdametinib is administered in the form of one or more 0.5 mg tablets, one or more 1 mg tablets, or any combination of any of the foregoing.

### Claim at position 19

19-21. (canceled)

### Claim 22 (depends on 15)

The method of claim 15, wherein the mirdametinib is administered in the form of one or more capsules.

### Claim at position 21

23-26. (canceled)

### Claim 27 (depends on 15)

The method of claim 15, wherein the patient is 2 to 15 years of age.

### Claim 28 (depends on 15)

The method of claim 15, wherein the patient is at least 16 years of age.

### Claim 29 (depends on 15)

The method of claim 15, wherein the method further comprises prior to treatment (i) determining whether to select mirdametinib as a treatment for the patient, and (ii) selecting mirdametinib as a treatment for the patient at least partially based on its objective response rate, where the objective response rate is defined as at least a 20% decrease in tumor size using centrally read MRI volumetric analysis.

### Claim 30 (depends on 29)

The method of claim 29, wherein in step (i), mirdametinib is selected based on a response rate of at least 70%.

### Claim at position 26

31-41. (canceled)

### Claim 42 (depends on 15)

The method of claim 15, wherein the mirdametinib is in the form of one or more dispersible tablets, and prior to administration, the one or more dispersible tablets are dispersed in water to form a suspension and optionally the suspension is swirled until no lumps remain.

### Claim 43 (depends on 42)

The method of claim 42, wherein the one or more dispersible tablets are dispersed in 5 to 10 mL of water to form the suspension.

### Claim 44 (depends on 42)

The method of claim 42, wherein the suspension is administered to the patient within 30 minutes of being prepared.

### Claim at position 30

45-48. (canceled)

### Claim 49 (depends on 1)

The oral dosage form of claim 1, wherein the mirdametinib has a d90 of no more 150 microns.

### Claim 50 (depends on 1)

The oral dosage form of claim 1, wherein the mirdametinib has a d90 of 50 to 150 microns.
